Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

This Phase I study tests a new type of CAR-T cell therapy called RC19D2 for patients with diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer. The therapy engineers a patient's own immune cells to target CD19, a protein on lymphoma cells, for people whose cancer has returned or not responded to prior treatments. **You may be eligible if...** - You are 18 or older - You have DLBCL confirmed to be CD19-positive - You have received at least two prior lines of treatment and your cancer has relapsed or is refractory - Your organ function is adequate **You may NOT be eligible if...** - You have active serious infections or significant organ failure - You have had prior CD19-targeted CAR-T therapy recently - You have uncontrolled brain involvement by lymphoma - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.